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Summary 
Identification of cytolytic T lymphocyte (CTL) epitopes presented by major histocompatibility 
complex (MHC) class I molecules on tumor cells is critical for the design of active immuno- 
therapy. We describe the use of combinatorial peptide hbraries with defined amino acids  in 
two MHC  anchor positions to search for epitopes that  are recognized by H-2D  b-  and K b- 
restricted  CTL  specific for the  mouse  lymphoma EL4.  An  iterative  strategy was  used  for 
screening hbraries in which 16 amino acids were divided into 3 groups and 3 subgroups: ot(AL, 
VT, FY); [3(GS, P, DE); y(KR, H, NQ). The proportions of each group and subgroup at indi- 
vidual peptide positions were changed in the library synthesis, and the effect of these changes 
on CTL activity was measured in a sensitive RMA-S cell assay. A single H-2D  b epitope mimic 
was deduced from the original library that contained >2  ￿  10  s potential peptides and was  at 
least 9 logs more potent than the original hbrary. Immunization of syngeneic mice with this 
peptide ehcited CTL that lysed EL4 cells as well as RMA-S cells pulsed with peptides isolated 
from D b molecules of EL4 cells, indicating functional similarity between the mimicking pep- 
tide and the naturally processed CTL epitope. Furthermore, adoptive transfer of such a CTL 
line had a therapeutic effect in mice with EL4 established as an ascites  tumor. Two H-2K  b- 
restricted epitope mimics of the  same  tumor were also  identified.  Our method represents a 
novel approach for the construction of MHC class I-restricted targets that can serve as immu- 
nogens for active immunotherapy of cancer. 
M 
ost antigens  recognized by CD8 + cytolytic T lympho- 
cytes  (CTL)  are derived from cytoplasmic proteins 
whose presentation involves the degradation by a protea- 
some  proteinase  complex into  small  peptides,  transporta- 
tion of peptides to the endoplasmic reticulum by peptide 
transporter-associated proteins, and binding to MHC class I 
molecules which then travel through the Golgi complex to 
reach the cell surface (1-3). The peptides are usually 8-10 
amino  acids  long,  with  2-3  primary anchor residues that 
interact with  the  MHC  class I  molecule  (4,  5),  and  2-3 
amino acid residues that bind to the TCR (6). Further anal- 
ysis of the requirement of MHC binding by a peptide indi- 
cates that several positions, besides the primary anchor and 
TCR binding amino acid residues,  can be replaced only by a 
limited number of amino acids,  suggesting a critical role of 
secondary anchor positions (7, 8).  Synthetic peptides have 
been used for the induction of specific CTL by immuniza- 
tion either in vitro or in vivo (9-13), and vaccination with 
peptides  can  induce  CTL-mediated  immune  responses 
against  tumors  (14,  15)  and  virus-infected  cells  (16)  in 
mice.  Identification of peptides that can elicit an efficient 
CTL response is, therefore, of practical importance for the 
development of immunogens for active immunotherapy of 
cancer. 
Several methods  have been  used  to  identify unknown 
CTL epitopes. If  the amino acid sequence of  a protein antigen 
is  known,  overlapping peptides  of 8-10  amino  acids  in 
length can be synthesized and screened as CTL targets, an ap- 
proach that has led to the discovery of a number of CTL 
epitopes derived from proteins of  viral origin (17). CTL epi- 
topes may also  be identified subsequent  to the search for 
MHC-binding motis and measurement of the affinity of  po- 
tential antigenic peptides for MHC molecules (18, 19). If the 
tumor antigen is not known, isolation of tumor-associated 
peptides from MHC class I molecules followed by purifica- 
tion and Edman sequencing (14,  20) or mass spectrometry 
(21) provides a direct way of  identifying CTL epitopes. Ge- 
netic approaches, such as the screening of DNA expression 
libraries,  provide another alternative and  have led  to  the 
discovery of several human and mouse antigens recognized 
by specific CTL (22, 23). In many situations, however, be- 
cause of the complexity and low abundance of the tumor 
epitopes presented,  the  application  of these  techniques is 
often time-consuming and sometimes problematic. 
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I-restricted CTL can be degenerate. This opens the possi- 
bility of using combinatorial peptide libraries to search for 
peptides that mimic naturally presented epitopes.  Analysis 
of several well-defined peptides that encode viral CTL epi- 
topes by synthetic peptide libraries indicates that only a cer- 
tain combination of amino acids is required for the interac- 
tion between MHC-peptide and TCR, whereas the amino 
acids in other positions can be  changed without affecting 
function (8,  24).  It is unclear from these studies, however, 
whether the peptide analogues can serve as functional mim- 
ics of the native peptide. We report here on combinatorial 
peptide libraries that were screened based on their ability to 
render RMA-S  cells  susceptible to  lysis by specific  CTL 
against  unknown  tumor  antigens.  The  EL4  mouse  lym- 
phoma system,  a  model that we  have  studied in the  past 
(25,  26),  was  used.  Using an  iterative  strategy,  effective 
peptides within the libraries were selected. Syngeneic mice 
immunized with  these  peptides  generated  K b-  and  D b- 
restricted CTL recognizing EL4 cells in vitro and in vivo. 
Materials and Methods 
Mice and Cell Lines.  Female  C57BL/6  mice,  6-8  wks  old, 
were purchased from Taconic Co. (Germantown, NY). The EL4 
lymphoma, which is of C57BL/6  (H-2b) origin, was purchased 
from American Type Culture Collection (Rockville, MD).  An 
EL4 line (B7 + EL4) expressing the costimulatory molecule B7-1 
was previously generated in our laboratory by infection of EL4 
cells with pLXSN recombinant retrovirus containing  murine B7-1 
cDNA (25). RMA-S, a peptide transporter-defective lymphoma 
line (27), is of C57BL/6 origin. P815.K  b and P815.D  b are clones 
from the P815 mastocytoma,  which had been transfected  to ex- 
press K  b or D b genes, respectively  (26). All cell lines were main- 
tained in vitro at 37~  in IMEM containing 10% fetal bovine se- 
rum (referred to as "medium"). 
Peptide Library Synthesis.  Peptide libraries were synthesized on 
either a peptide synthesizer  (model 430A;  Applied Biosystems, 
Inc., Foster City, CA) using Boc amino acids or on a multiple pep- 
tide synthesizer  (model AMS 422;  Gilson Electrical  Med.  Inc., 
Middleton, WI) using Fmoc amino acids (28). Peptide mixtures 
corresponding to the D b motif  were synthesized only by the Fmoc 
strategy, whereas peptide mixtures corresponding to the K  b motif 
were synthesized by a mixed Fmoc and Boc strategy. The anchor 
residue positions (5) for K  b peptide libraries were fixed at 5 (F, Y) 
and 8 (L) or for D b peptide libraries at 5 (N) and 9 (L), while all 
other positions were variable. 
￿9 The strategy for synthesis was the same as previously described 
(29). Briefly, the variable X position corresponded to an approxi- 
mately equimolar incorporation of 16 amino acids by a simulta- 
neous coupling of the appropriate  mixture which, when Fmoc 
amino acids were used, was e~(A/L/V/T/F/Y ratio  1:1.2:2:2:1.3: 
1.3);  [3(G/S/P/D/E/  ratio  1:1:1.3:1:1);  ~/(K/R/H/N/Q  ratio 
1.3:2:1.6:1.3:1.3).  Peptides  were  cleaved  from  the  resin  and 
deprotected  by  a  2-h  reaction  with  TFA/water/thioanisole/ 
ethanedithiol (100:5:5:2.5).  After  precipitation from cold ether, 
the precipitates  were dissolved in formic acid and either diluted 
with water and lyophilized (library mixtures),  or they were puri- 
fied as single peptides by reverse-phase  HPLC with a gradient of 
acetonitrile in 0.1%  TFA.  A  previously described  Th  epitope, 
HBVc  128-140/I-A  b (TPPAYRPPNAPIL) (30), was synthesized 
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and used for immunization. A Kb-binding  peptide, KHYKIRNL, 
from the murine p56  lck sequence (31) was used as a control. Sin- 
gle peptides  were analyzed  on a Biolon AB  mass spectrometer 
(Uppsala, Sweden). 
Peptide libraries  with the  K  b motif were  synthesized  by the 
Boc strategy as described previously (29). Free peptides were ob- 
tained from the peptide resin by reaction with 90% hydrogen fluo- 
ride/10% anisole for 1 h at 0  ~ After evaporation of hydrogen fluo- 
ride,  the  peptide-resin mixture was washed  with ethyl acetate, 
and the peptides  were dissolved in 50% acetic acid and obtained 
as a dry powder after lyophilization from 5% acetic acid. When 
the peptide libraries had been reduced to a mixture of 64 peptides 
(two possibilities at each of six positions;  Fig.  1 B), peptide syn- 
thesis was done by the Fmoc strategy as described above. All sub- 
sequent libraries and individual peptides  were synthesized by this 
method. 
Isolation and  Purification of MHC  Class 1-associated Peptides. 
Natural peptide  mixtures and purified peptides  from EL4  cells 
were prepared from either H-2K  b or D b proteins by a combina- 
tion of affinity chromatography  and reverse-phase HPLC,  as de- 
scribed (26). 
Assays for CTL Activity.  Peptide libraries, individual peptides, 
and peptide fractions  eluted from either K  b or D b molecules  of 
EL4  cells (26) were reconstituted in PBS and further diluted in 
medium. RMA-S cells were incubated at 22~  for 48 h, labeled 
with SlCr at 22~  for 2 h, and incubated with peptides in 96-well 
V-shaped plates at 37~  for 1.5 h, after which they were used as 
targets for lysis by CTL.  C2D is a CD8  + CTL line specific for 
EL4 cells and reacts with a single peptide isolated from D b mole- 
cules  (26). 4A2  is an EL4-specific  CD8 +  CTL clone that was 
generated from a mouse that had been immunized with B7 + EL4 
cells (25, 26). It recognizes a single peptide isolated from K  b mol- 
ecules (see Fig. 3). The CTL activity was examined in a standard 
4-h SlCr release assay with different E/T ratios as indicated. 
Generation  of  CTL  by  Immunization  of  Mice with  Peptides. 
C57BL/6  mice  were  injected subcutaneously with  peptides  at 
100  Ixg/mouse emulsified  in IFA,  with or without mixing the 
peptides with 100 Ixg of the HBVc 128-140/I-Ab Th peptide.  14 d 
later,  spleen  cells were prepared and stimulated with B7 + EL4 
cells for 5 d as described  (25). In some experiments, the bulk-cul- 
tured spleen cells were restimulated  in vitro every 7-10 d,  and 
their cytolytic  activity  was examined in a standard  4-h SlCr re- 
lease assay. 
Adoptive Transfer of the Mimicking Peptide-induced CTL for Treat- 
ment of Ascitic EL4 Tumor.  The method of adoptive transfer  of 
CTL for treatment of established tumors has been described pre- 
viously (32, 33). Briefly, C57BL/6 mice, in groups of five, were 
injected intraperitoneally with 105 EL4 cells. 3 d later, the mice 
were injected with 5  ￿  106 cells of an EL4pepI-induced CTL 
line, followed on day 4 by an injection of 2,000  U  i.p.  human 
rlL-2 (Cetus Corp., Emeryville, CA) every day for 3 d. The con- 
trol groups  were injected with either IL-2 alone or IL-2 with a 
control CTL line that was specific for EL4peplI-A and lost CTL 
activity in in vitro cultures.  The mice were monitored daily for 
survival. 
Results 
Strategy for  the  Synthesis  of Combinatorial  Peptide  Librar- 
ies.  We applied an iterative strategy (29)  by dividing the 
16 amino acids into three groups: ec(AL, VT, FY); [3(GS, P, 
DE); ~/(KR, H,  NQ),  and each group was further divided 
into  three  subgroups  as  can  be  noted  by  the  grouping 
I-restricted  Epitope Mimics within the parentheses.  Four amino acids, C, M, I, and W, 
were  omitted  from the  library  for reasons  previously  de- 
scribed  (29).  In addition,  M,  I,  and W  were  expected  to 
decrease the solubility of the library, possibly to a concen- 
tration  too low to enable  us to detect biological response. 
The  significance  of our three-group  strategy  is  that  it  al- 
lowed a simultaneous  decrease  (to 0)  in the proportion of 
one group, an increase  (two- to threefold,  as indicated)  in 
the  proportion  of a  second group,  and  no  change  in  the 
proportion of the third group at each of the variable residue 
positions in the peptide library. The effect of these changes 
on  the  biological  activity  of the  peptide  library  indicated 
which of the groups, or amino acids within the groups, was 
contributing  the  most  to  the  observed  biological  effect. 
Thus,  a  decrease  in  activity indicated  that  the  first  group 
was  most important,  an increase  in activity indicated  that 
the  second group was most important,  and an unchanged 
activity indicated that the third group was the most impor- 
tant. A repeat of the iterative strategy with the correspond- 
ing subgroups ultimately allowed the deduction of a single, 
highly active peptide. 
Screening of Peptide Libraries for I~-  and  I~-restricted Epi- 
topes Recognized by EL4-specific CTL.  We first  screened the 
peptide  library by a  Db-restricted  CTL line,  C2D,  which 
lyses EL4 cells  (26). The starting library was X-X-X-X-N- 
X-X-X-L,  where  X  corresponded  to  any  of 16  possible 
amino acids.  This library consisted  of a mixture  of 167  = 
268,435,456 peptides.  The mixed peptides from this library 
were loaded onto RMA-S cells whose sensitivity to lysis by 
the C2D CTL was examined.  No significant lysis was ob- 
served (Fig. 1 A, curve  1). In an attempt to increase the sol- 
ubility of the library, we examined paired substitutions,  DE 
or KR,  at  each  of the  variable  X  positions.  As shown  in 
Fig.  1 A  (curve  2),  substitution  of DE  at position  7  gave 
slightly increased activity.  Substitution  of DE  at the  other 
positions had no effect on activity, as was also observed for 
the corresponding substitution of KR (data not shown). 
The  library  with  the  DE  substitution  at  position  7 
(33,554,432 peptides), X-X-X-X-N-X-DE-X-L,  was sub- 
jected  to  an iterative  strategy of variation.  Each of the  X 
positions was substituted with c~2. This corresponded to a 
decrease (to 0) in the 13 group amino acids (G, S, P, D, E), 
an increase (twofold) in the ~/group amino acids (K, R, H, 
N, Q), and no change in the o~ group of amino acids (A, L, 
V, T, F, Y). The results of these substitutions are shown in 
Table 1. Substitution of ot~/2 at positions 1, 6, and 8 had lit- 
de effect, indicating that the ot group was preferred at these 
positions; substitution of or  at position 4 decreased activ- 
ity, indicating that the  13 group was preferred; substitution 
of ~x~/2 at  positions  2  and  3  increased  activity,  indicating 
that  the  ~/  group  was preferred.  This  suggested that  a  re- 
duced library of 54,000 peptides  corresponding to ot-~/-~/- 
13-N-ot-DE-ot-L would be more active. When a parallel it- 
erative procedure was conducted by substituting 132~/at each 
of the  X  positions,  the  results  were in agreement at posi- 
tions  1,  4,  6,  and  8,  but  differed  for  positions  2  and  3, 
where ot was preferred (data not shown). Two possibilities at 
each  of two  positions  indicated  four  combinations  that 
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Figure 1.  Increased potency of mimicking peptides in sensitization of 
RMA-S cells for lysis by EL4 antigen-specific CTL. Peptide libraries were 
reconstituted in PBS and further diluted in medium before use, as indi- 
cated. RMA-S cells were kept at 22~  for 48 h, labeled with SlCr at 22~ 
for 2 h, and incubated with peptides in 96-well V-shaped plates at 37~ 
for 1.5 h. They were then incubated with the EL4-specific,  Db-restricted 
CTL line C2D (A) or with the Kb-restricted CTL clone 4A2 (B) at an E/T 
ratio of 2:1. The cytolytic activity was examined in a standard 4-h SlCr 
release assay; background cpm (incubation of T ceils and RMA-S cells 
without peptide) was subtracted. (A) The original library (labeled as  I) 
was X-X-X-X-N-X-X-X-L; three intermediate libraries (labeled as 2, 3, 
and 4) were X-X-X-X-N-X-DE-X-L; a-~/-~/-[3-N-a-DE-cx-L  and AL- 
NQ~H-P-N-AL-DE-AL-L  and  the  final peptide (labeled  as  5)  is 
EL4pepL (/3): The original library (labeled as I) was X-X-X-X-FY-X-X- 
L (33,554,432 peptides); three intermediate libraries (labeled as 2, 3, and 
4) were KR-X-X-X-FY-X-X-L (4,154,304 peptides), KR.-'y-et-e~-FY- 
"y-'y-L (18,000 peptides), KR-H-FY-AL-FY-KR-NQ-L (64 peptides), 
and the final peptide (labeled as 5) is EL4peplI. 
needed to be investigated.  Each of these libraries  was syn- 
thesized and the results (data not shown) showed all the new 
libraries  to be more active than the 33,554,432-peptide  li- 
brary. The library with ~/at positions 2 and 3 was the most 
active and had an activity several orders of magnitude greater 
than that of the 33,554,432 library (Fig.  1 A, curve 3). 
The  54,000-peptide  library  (ot-~/-~-13-N-ot-DE-ot-L) 
was subjected to further modifications (Table 2) by a logi- 
cal division  of each  of the  et,  13,  and  ~/  groups  into  their 
component subgroups. Substitution of (AL)2VT at positions 
1,  6,  and  8  increased  the  activity  indicating  that  AL was 
preferred  at  each of these positions.  Substitution  of GSP3 
(threefold increase ofproline) at position 4 also showed in- 
creased activity indicating that P was preferred at that posi- Table 1.  Lysis of RMA-S Cells Pulsed with Peptide Libraries by a H-2~restricted CD8+ CTL Line C2D 
Peptide library sequence*  Deduced 
Concentrations  Percent  Critical 
1  2  3  4  5  6  7  8  9  (-log M)  lysis~  Residuesll 
No peptide  0.6 
X  X  X  X  N  X  DE  X  L  5  16.2 
6  15.5 
8  1.8 
or  2  X  X  X  N  X  DE  X  L  5  17.8  (x 
6  12.9 
8  2.5 
X  oLy  2  X  X  N  X  DE  X  L  5  38.9  y 
6  30.1 
8  9.0 
X  X  oty  2  X  N  X  DE  X  L  5  27.0  "/ 
6  29.1 
8  9.9 
X  X  X  oty  2  N  X  DE  X  L  5  8.1  [3 
6  4.2 
8  2.7 
X  X  X  X  N  o~y  2  DE  X  L  5  24.3  c~ 
6  20.6 
8  2.4 
X  X  X  X  N  X  DE  oLy  2  L  5  29.9  (x 
6  19.3 
8  3.6 
*  The intermediate libraries were synthesized with the X position incorporating an approximately  equimolar mixture of 16 amino acids by a simulta- 
neous coupling of the appropriate  mixture, and with a position (cey2) replaced by the (x group of amino acids (AL, VT, FY) and twofold  of the 
group amino acids (KR, H, NQ), but omitting the [3 group amino acids (GS, P, DE). 
*Peptide hbraries were reconstituted in PBS and further diluted in medium. RMA-S cells were incubated at 22~  for 48 h, labeled with 51Cr at 
22~  for 2 h, and incubated with peptides at molar concentration as indicated in 96-well V-shaped plates at 37~  for 1.5 h. 
~The lysis of the peptide-pulsed RMA-S cells by a H-2b-restricted CD8 + CTL line C2D was examined in a standard 4-h 51Cr release assay. E/T ra- 
tio =  4:1. 
liThe effect of o~',/2 amino acid substitution ofpeptide libraries on CTL activity was evaluated in comparison with the library X-X-X-X-N-X-DE- 
X-L. A decrease in CTL activity indicated tha the 13 group was most important, an increase in activity indicated that the 3' group was most impor- 
tant, and an unchanged activity indicated that the c~ group was the most important.  In this round screening, the deduced library was: oL-~/-y-13-N-o~- 
DE-o~-L. 
tion.  The  corresponding substitutions at positions 2  and 3 
gave equivocal results similar to our observation in the first 
iteration. As seen in Table 2,  it was difficult to  distinguish 
between Kt< and NQ.  Other  data indicated that histidine 
was  preferred  at position 3  (data  not shown).  Thus,  there 
were  2  ￿  3  =  6  possible combinations to investigate, and 
each  of the  corresponding libraries  was  synthesized.  The 
results  indicated that  the  32  (25)  peptide  library AL-NQ- 
H-P-N-AL-DE-AL-L  was the most active (Fig.  1 A, curve 
4).  Finally, single amino acid substitutions (Table 3)  indi- 
cated  that  the best single peptide  was AQHPNAELL  (re- 
ferred to as EL4pepI;  Fig.  1 A,  curve 5). A  comparison of 
the  ability to  sensitize RMA-S  for lysis by the  C2D  CTL 
line  between  EL4pepI  and  the  various  libraries  indicates 
that the activity of EL4pepI  was at least 9  logs higher than 
that of the starting library (Fig.  1 A). 
A  similar strategy was  used to  search  for a  Kb-restricted 
CTL epitope.  The starting library with the K b motif X-X- 
X-X-FY-X-X-L  contained 33,554,432  (2  ￿  166) peptides. 
For screening, we used either the anti-EL4 CTL clone 4A2, 
which  had  been  obtained by limiting dilution cloning of 
bulk-cultured spleen cells from C57BL/6 mice immunized 
with B7 § EL4 cells (26) or bulk-cultured polyclonal T  cells 
(25).  Paired substitutions of KR,  DE,  or NS  at position  1 
showed that  the KR  substitution slightly increased the ac- 
tivity of the library. The reduced library KP,-X-X-X-FY- 
X-X-L  was subjected to  the iterative process.  Substitution 
of each  of the  five  remaining X  positions  with  [~2Y, fol- 
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Peptide library sequence* 
Concentration 
1  2  3  4  5  6  7  8  9  (-log  M) 
Deduced 
Percent  critical 
lysis  residues 
No peptide 
N  ix  DE  ot  L 
(AL)2VT  "/  "/  [3  N  ot  DE  ot  L 
oL  KRH3  "/  [3  N  oL  DE  ee  L 
o~  "y  KRH 3  [3  N  o~  DE  o~  L 
oL  y  31  GSP 3  N  oL  DE  o~  L 
oL  ~/  ~  [3  N  (AL)2VT  DE  o~  L 
o~  ~  ',/  [3  N  o~  DE  (AL)2VT  L 
0 
8  73.5 
10  10.4 
12  0 
8  72.5  AL 
10  41,9 
12  8.9 
8  68.3  KIL, NQ 
10  3.9 
12  2.0 
8  68.3  KR, NQ 
10  0.8 
12  0 
8  75.2  P 
10  82.6 
12  11.0 
8  78.0  AL 
10  74.1 
12  32.8 
8  77.6  AL 
10  79.0 
12  29.0 
*The intermediate libraries were synthesized and assayed as described in the legend to Table 1, except that amino acids in the subgroups from each 
cx, 13, and ~/group were used for substitution. E/T ratio =  4:1. 
lowed  by  subgroup  iterations,  ultimately  led  to  a  single 
highly active peptide, KHYLFRNL (referred to as EL4peplI). 
The results  are summarized in Fig.  1 B,  and the EL4peplI 
has  a potency "~8  logs higher  than  that  of the  starting li- 
brary. 
Induction  of CTL Specific  for EL4 Cells by Immunization with 
Epitope Mimics.  The two peptides EL4pepI and EL4peplI 
were used in an attempt to generate CTL against EL4 cells 
by immunizing C57BL/6 mice. Immunization with EL4pepI 
alone gave a weak CTL response against EL4 cells.  How- 
ever, injection of a mixture of  EL4pepI and the helper pep- 
tide  HBVc  128-140/I-A  b  elicited  a  strong  CTL  activity 
against EL4 cells,  whereas immunization with HBVc 128- 
140/I-A  b  alone  did  not  induce  any  CTL  response.  The 
CTL appeared  to be specific for EL4 cells,  since the  P815 
mastocytoma line was not lysed. In contrast, immunization 
of mice with  either  EL4peplI  alone  or a  combination  of 
EL4peplI and HBVc 128-140/I-A  b did not induce any de- 
tectable EL4-specific CTL response (Table 4). 
The  failure  of EL4peplI  to  elicit  an EL4-reactive  CTL 
suggested that it differed in the structure from the naturally 
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processed peptide.  We  observed that  substitution  of posi- 
tion 1 with A, L, G, T, S, or N  had no effect on the activity 
in the  tLMA-S assay (data  not shown),  whereas  all  of the 
other positions were sensitive to change. Substitution ofala- 
nine at position 2 reduced activity substantially, substitution 
ofalanine at position 3-8 reduced it much more, and con- 
servative changes at positions 3, 4, 6, and 7 gave peptides with 
significantly reduced activity (data not shown). When a mix- 
ture of  four peptides, EL4peplI-A, EL4peplI-L, EL4peplI-G, 
and EL4peplI-T (corresponding to EL4pepII with the amino 
terminal lysine substituted with the respective indicated amino 
acids),  was  used  to  immunize  mice,  CTL  that  lysed EL4 
cells,  but not P815.K  b cells,  could be generated  (Fig. 2 A). 
Further  analysis  demonstrated  that  these  CTL  recognized 
EL4peplI-A  and  EL4peplI-T,  but  not  EL4peplI-G  or 
EL4peplI-L  (Fig.  2  B).  Immunization  with  EL4peplI-A 
or EL4peplI-T individually also induced EL4-specific CTL, 
whereas immunization with the control mlck peptide, which 
has a similar amino acid composition to EL4peplI and binds 
to  K b molecules,  did  not  (Fig.  2  C).  The potency of the 
EL4peplI  variants  was further  enhanced by immunization Table 3.  Lysis  of RMA-S cells Pulsed with Peptide Libraries by a H-2~restricted CD8  + CTL Line C2D* 
Peptide library sequence  Deduced 
Concentration  Percent  critical 
1  2  3  4  5  6  7  8  9  (-log M)  lysis  residues 
No peptide  0.9 
AL  NQ  H  P  N  AL  DE  AL  L  8  90.3 
10  69.6 
A  NQ  H  P  N  AL  DE  AL  L  8  83.3  A 
10  84.5 
AL  N  H  P  N  AL  DE  AL  L  8  29.7  Q 
10  3.5 
AL  NQ  H  P  N  A  DE  AL  L  8  97.0  A 
10  91.4 
AL  NQ  H  P  N  AL  E  AL  L  8  86.5  E 
10  78.1 
AL  NQ  H  P  N  AL  DE  A  L  8  3.2  L 
10  4.5 
*The intermediate libraries  were synthesized  and assayed as described in the legend to Table 1. E/T ratio =  4:1. The deduced library was A-Q-H- 
P-N-A-E-L-L and designated as EL4pepI. 
together with the HBVc 128-140/I-A  b helper peptide (Ta- 
ble 5).  Our results indicate that CTL induced by the mim- 
icking peptides could recognize EL4 cells. 
Recognition of Naturally Presented EL4 Peptides by the Mim- 
icking Peptide-induced CTL.  To demonstrate whether CTL 
induced by the mimicking peptides could recognize natu- 
Table 4.  Induction  of EL4-specific CTL by the Mimicking 
Peptides EL  4pepI and EL4peplI 
Peptide* 
% Specific lysis/E:T ratio* 
EL4  P815 
HBVc 128-140/I-A  b  10:1 5:1  1:1  10:1 5:1  1:1 
None  Yes  -~  4.3  0.7  -  1.4  1.3 
EL4pepI  No  16.6  -  3.5  2.3  -  0.7 
EL4pepI  Yes  65.0  -  58.3  5.1  -  1.1 
EL4peplI  No  1.6  -  0.0  3.1  -  0.8 
EL4peplI  Yes  19.0  -  5.3  16.0  -  1.3 
*Spleen cells were prepared from the mice immunized with the pep- 
tides and were cocultured with B7 § EL4 cells for two cycles of stimula- 
tion (7 d for each cycle). The cells  were then tested for their CTL activ- 
ity on EL4 and P815 cells in a standard 4-h SlCr release assay. 
*C57BL/6 mice were injected subcutaneously  with the indicated pep- 
tides at 100 Ixg/mouse with or without 100 Ixg of HBVc 128-140/I-A  b 
Th peptide in IFA. 
~Not done. 
rally processed peptides on EL4 cells, we purified from EL4 
cells  both  K b-  and  Db-associated  peptides.  Lysates  were 
prepared from in vitro-cultured EL4 cells, and the peptide- 
MHC  class I complex was purified by affinity chromatog- 
raphy  using  mAbs  to  either  K b  or  D b,  after  which  the 
eluted peptides were fractionated by reverse-phase HPLC. 
Individual peptide fractions were loaded onto RMA-S cells 
to sensitize them for lysis by CTL that had been induced by 
the mimicking peptides. The EL4pepI-induced CTL lysed 
RMA-S cells pulsed with fraction 8, 9, and 10 of peptides 
eluted from D b molecules, while they did not react with 
the other fractions. This recognition pattern was not iden- 
tical, but similar to that of the  C2D  CTL line (Fig. 3 A). 
The EL4pepII-A-elicited CTL, similarly to the 4A2 CTL 
clone, specifically recognized fraction 9  of peptides eluted 
from K t' molecules (Fig. 3 B).  Our results demonstrate that 
immunization  of mice with mimicking peptides can induce 
CTL that cross-react with natural tumor epitopes presented 
by EL4 cells. 
Treatment of an Established Ascites EL4 Tumor by Adoptive 
Transfer of the Mimicking Peptide-induced CTL.  To  deter- 
mine  whether  the  CTL  elicited  by  mimicking peptides 
could be  used for treatment of an  established tumor,  we 
used a model in which the injection of C57BL/6 mice in- 
traperitoneally with EL4 cells at 105/mouse led to the rapid 
growth of EL4 cells as an ascites tumor. Mice treated with 
either IL-2 only or IL-2 combined with a control CTL line 
all died with ascites within 49 d of tumor cell injection. In 
contrast,  among  five  mice  treated  with  an  EL4pepI- 
induced CTL line plus IL-2, two mice died with large as- 
citic tumors on days 53 and 59, respectively, and the three 
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Figure 2.  Induction ofEL4-specific  CTL by immunization  with variant peptides derived from EL4pepll.  C57BL/6 mice were injected subcutaneously 
with a mixture of peptide EL4peplI-A, EL4peplI-L,  EL4pepII-G,  and EL4peplI-T at 100 t~g, each emulsified in IFA in a 0.05-ml vol. 2 wk later, spleen 
cells from immunized mice were harvested and stimulated twice in vitro with ~/-irradiated B7 + EL4 cells for 14 d. The cytolytic activity of the cultured 
spleen cells was examined against EL4 cells or P815.K b cells at the indicated E/T ratios (A) or against RMA-S cells pulsed with individual peptides, as in- 
dicated, at an E/T ratio of 1:1 (B). In both cases, a standard 4-h SlCr release assay was used. Mice were also immunized with an individual peptide from 
the control peptide  mlck, EL4peplI-A, or EL4pepI-T at 100 I~g, and spleen cell cultures were prepared as described above. The cytolytic activity of the 
cultured spleen cells was examined against EL4 cells or P815 cells at an E/T ratio of 2:1 (C). 
remaining  mice  were  alive  and  had  no  sign  of tumor  on 
day  140,  when  the  experiment  was  terminated  (Fig.  4). 
Similar results  were  obtained  in  another  experiment  with 
five mice per group. 
Table  5.  Induction  of EL4-specific CTL by the Variants of 
EL  4peplI 
Percent specific lysis/E:T ratio* 
EL4  P815 
HBVc 
Peptide*  128-140/I-A  b  10:1  5:1  1:1  10:1  5:1  1:1 
None 
mlck 
EL4peplI-A 
EL4pepII-T 
Yes  -9  9.4  1.6  -  0.0  0.0 
No  -  0.0  0.0  -  0.7  0.0 
Yes  -  8.3  4.6  -  0.0  0.0 
No  20.1  -  4.5  3.2  --  0.3 
Yes  67.6  -  54.3  0.3  -  0.0 
No  61.5  55.6  40.7  3.0  0.9  0.2 
"Spleen cells were prepared from the mice immunized with the pep- 
tides and were cocultured with B7 + EL4 cells for a stimulation  cycle of 
7 d. After five cycles of stimulation,  the cells were tested for their CTL 
activity on both EL4 and P815 cells in a standard 4-h SlCr release assay. 
*C57BL/6  mice were  injected subcutaneously  with  two  variants  of 
EL4peplI, EL4peplI-A, and EL4peplI-T, or a control peptide mlck at 
100  p,g/mouse  with  or without  100  ~g of HBVc  128-140/I-A  b T 
helper peptide in IFA. 
~Not done. 
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Discussion 
Using combinatorial peptide hbraries, we have identified 
several functionally active peptides that  can mimic the epi- 
topes  of tumor-associated  antigens  recognized by  K b-  and 
Db-restricted CTL  and are specific for the EL4 mouse lym- 
phoma.  The  mimicking peptides  are  recognized  by  CTL 
that  were  raised by immunizing mice with B7 +  EL4 cells, 
and  they  can  induce  CTL  responses  against  EL4  cells.  In 
principle,  this method  can be  used  to  construct  functional 
epitope mimics, provided that  the presenting MHC  mole- 
cules and the peptide-binding motif, are known.  It thus rep- 
resents a novel approach for exploring new targets for T  ceU- 
mediated immunotherapy  of cancer. 
Based on the motif and affinity ofpeptides to MHC  class I 
molecules,  a  number  of them  have  been  successfully pre- 
dicted from known proteins such as potential CTL epitopes 
(17-19).  However,  additional  parameters  appear  to  con- 
tribute  to  what  constitutes  a  CTL  epitope.  For  example, 
some  peptides  predicted  by  their  motif are  nonimmuno- 
genic (34), or they are immunogenic, but the CTL induced 
by them do not react with naturally presented peptides  (19, 
35).  In addition,  not all high affinity peptides are immuno- 
genic  (19,  36).  We  showed previously that  the  C2D  CTL 
fine recognizes a subdominant  epitope that can only induce 
a  CTL  response  in  the  presence  of costimulation  by  B7- 
CD28 interaction (26).  The apphcation of the iterative strat- 
egy using a  multiple peptide  synthesizer  for rapid  simulta- 
neous synthesis ofhbraries, and the stable Db-restricted CTL 
clone C2D  for screening,  enabled us to find a  single active 
peptide  (EL4pepI)  in  ,'o10  wk.  The  CTL  induced  by ,--a 
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Figure  3.  Immunization with the 
mimicking peptides can induce CTL 
that  recognize  naturally  processed 
peptides  on  EL4  lymphoma.  Re- 
verse-phase  HPLC  was  used for 
preparation and fractionation of K  b- 
and Db-associated peptides from in 
vitro-cultured  EL4  cells,  as  de- 
scribed in the Materials and Meth- 
ods. The CTL line C2D (A) or 4A2 
(/3) was tested for cytolytic activity 
on KMA-S cells pulsed with  indi- 
vidual HPLC  fractions from  either 
13  b (A) and K  b (/3). Individual HPLC 
fractions were  reconstituted in  200 
I*l PBS and 1% aliquots were used to 
pulse KMA-S target cells. The E/T 
ratio was 4:1. 
EL4pepI are MHC  class I restricted, express CD8  (data not 
shown), and can lyse EL4 cells (Table 4) as well as 1LMA-S 
cells pulsed with  naturally presented peptides eluted from 
D b molecules of EL4 ceils (Fig. 3 A), but fail to lyse an allo- 
geneic tumor, P815, or H-2D b transfectant P815.D b (data not 
shown).  Similar results  were  obtained  using  EL4pepII-A 
and EL4pepII-T (Figs. 2,  B  and  C,  and 3  B).  It has yet to 
be  determined whether  the mimicking peptides are more 
potent inducers of CTL  than naturally processed peptides. 
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Figure 4.  Treatment of mice with EL4 ascites  tumor by adoptive trans- 
fer of EL4pepI-induced CTL. C57BL/6, in groups of five, were injected 
intraperitoneally with 105 EL4 cells. 3 d later, they were injected intra- 
peritoneally with 5 ￿  10  6 cells of an EL4pepI-induced CTL line followed 
the next day by an injection of 2,000 U i.p. of human rlL-2; the IL-2 in- 
jection  was  repeated once  a day for three  consecutive days. Control 
groups were injected with either IL-2 or IL-2 combined with a control 
CTL line. The mice were monitored daily for survival, and the experi- 
ment was terminated on day 140 after tumor injection. 
However, the use of combinatorial peptide libraries repre- 
sents a  rapid and reliable approach to determine the func- 
tional mimicries of unknown CTL epitopes. 
Although EL4pepI itself did not produce  a  strong CTL 
response  in  syngeneic  mice,  injection  of the  peptide  to- 
gether  with  the  Th  epitope  HBVc  128-140/I-A  b  (30), 
however,  did induce  a  potent  CTL  response  against EL4 
cells  (Table  4).  Similarly,  a  P815  tumor-associated  non- 
apeptide (37) did not induce CTL unless a Th epitope was 
included  in  the  immunization  (38).  These  results  under- 
score the importance of Th  cells in the induction of EL4- 
specific CTL by peptides. 
EL4pepII  was  found  to  be  highly  active  in  sensitizing 
RMA-S cells for lysis by CTL, indicating that it can trigger 
the cytolytic machinery through TCP, ligation. However, 
CTL  induced by immunization of mice with this peptide 
did  not  lyse  EL4  cells  (Table  4),  although  they  can  lyse 
EL4peplI-pulsed  RMA-S  cells  (Johnston,  J.V.,  J.  Blake, 
and  L.  Chen,  unpublished  data).  Furthemaore,  at  least 
seven analogues of EL4peplI that differed only at position 1 
were  capable of sensitizing RMA-S  cells, but only two  of 
those  (EL4pepII-A  and  EL4pepII-T)  elicited  CTL  that 
cross-reacted with EL4  cells (Fig. 2).  These  results suggest 
that EL4pepII is immunogenic  and  argues  that  the  failure 
of the peptide to induce anti-EL4 CTL was not caused by 
an inappropriate immunization. In many cases, high affinity 
ofa peptide to the MHC  class I molecule is correlated with 
its  immunogenicity  (36).  Our  preliminary  experiments 
showed  that  EL4pepII-A binds  H-2D  t'  better  than  EL4- 
peplI (Johnston, J.V., J.  Blake, and L. Chen,  unpublished 
data), suggesting this possibility. 
Adoptive transfer of a  CTL  line from mice  immunized 
with EL4pepI inhibited the growth of EL4 cells as an ascitic 
tumor  and  prolonged  the  survival  of the  tumor-bearing 
mice (Fig. 4), indicating that CTL induced by the mimick- 
ing peptide can destroy EL4 cells in vivo. Experiments are 
128  Major Histocompatibility  Class I-restricted Epitope Mimics underway to investigate  the  effect of the  mimicking pep- 
tides in the induction of antitumor immunity in vivo. Pre- 
liminary  data  indicate  that  a  weak  protective  immunity 
against  challenge  of EL4  cells  can  be  achieved  by simply 
immunizing with a mixture of EL4peplI-A with IFA. The 
efficacy of immunization with mimicking peptides can prob- 
ably be further increased by presenting them in conjunc- 
tion with costimulation provided by B7-CD28 interaction 
(39, 40) or by immunizing peptide-pulsed dendritic cells (41). 
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